Summary
The novel F-18 cardiac amyloidosis PET tracers highlighted at ESC 2026 reduce effective radiation dose by half (~2 mSv vs ~4.5 mSv) compared to conventional Tc-99m SPECT while providing sub-4mm spatial resolution and quantitative SUV metrics.1, 2At the European Society of Cardiology (ESC 2026) Congress, novel F-18 amyloid PET radiopharmaceuticals drew significant attention for diagnosing transthyretin cardiac amyloidosis (ATTR-CM).1
From a medical physics standpoint, transitioning from Tc-99m SPECT to F-18 PET delivers:
- 50% Radiation Dose Reduction: Administered activity drops from ~740 MBq to ~200 MBq, cutting effective dose from ~4.5 mSv to ~2.2 mSv.2, 3
- Higher Detection Sensitivity: Coincidence timing eliminates lead collimators, capturing more emitted photons.
- Quantitative Accuracy: True SUV quantification tracks therapeutic response over time.1
References
- European Society of Cardiology (ESC) Congress 2026. Novel F-18 PET radiopharmaceuticals for targeted imaging of transthyretin cardiac amyloidosis (ATTR-CM). Clinical Science Special Session, August 2026.
- Dorbala S, et al. ASNC/EANM/SCMR/SNMMI guideline for the diagnosis of cardiac amyloidosis. J Nucl Cardiol 2021; 28:1309–1355.
- ICRP. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 128, Ann. ICRP 44(2), 2015.
- İlişkili DoseSave yazıları: PET/BT Sonrası Radyasyon Yayılımı · Efektif Doz · Radyasyon Birimleri
Sıkça Sorulan SorularFrequently Asked QuestionsHäufig gestellte FragenPreguntas frecuentes
What is the radiation dose advantage of cardiac PET over SPECT in amyloidosis?
Traditional Tc-99m PYP scintigraphy (~740 MBq) delivers an effective dose of 4 to 5 mSv. In contrast, F-18 PET tracers use lower administered activities (~185-250 MBq) and, due to the short 110-minute half-life, reduce patient effective dose to approximately 2.0 to 2.5 mSv.
Note: This content is for education; for clinical decisions or regulatory compliance, consult a qualified medical physicist and current regulations.